Advanced Cancer Clinical Trial
Official title:
Locus of Control and Spirituality in Palliative Care Patients
Primary Objectives:
1. To determine whether the degree of spirituality/religiosity as determined by the Duke
University Religion Index and Functional Assessment of Chronic Illness Therapy-Spiritual
Well Being Scale (FACIT-Sp) correlates with internal locus of control as determined by
the Locus of Control Scale.
2. To determine the relationships among spiritual-well being, religiosity, hope,
depression, and culture, socioeconomic status, and gender in a palliative care setting.
3. To determine if hope and depression in palliative care patients are affected by the
degree of intrinsic and extrinsic spirituality/religiosity.
4. To determine if patients who believe in predestination correlate with decreased locus of
control, but improved quality of life and degree of religiosity.
If you are receiving care in the Palliative Care clinic and are eligible to participate, you
will be asked to fill out one-time quality of life surveys, which will take about 40 minutes
to complete. The Functional Assessment of Chronic Illness Therapy (FACT-G) survey asks
questions about physical and emotional well-being, functional well-being (how much you
participate in and enjoy normal daily activities), and social/family well-being.
This study first collected questionnaires from 100 participants from different racial and
ethnic backgrounds. When the questionnaires were compared, investigators found some
interesting differences between the African American and Caucasian participants. To better
understand these findings, an additional 67 African American patients are needed to compare
the groups.
The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACT-Sp)
asks questions about personal meaning, faith and peace. The Duke University Religion Index
(DUREL) asks questions about religious practices. The Locus of Control (LOC) questionnaire
asks questions about personal internal control, your views on chance, and your views on
power. The Herth Health Scale (HHS) asks questions about hope. The Edmonton Symptom
Assessment System (ESAS) asks questions about symptoms you may be experiencing. The Hospital
Anxiety and Depression Scale (HADS) asks questions about your feelings of depression and
anxiety. The "predetermination" questionnaire asks questions about your beliefs about your
fate.
These eight questionnaires will take about 40 minutes to complete and may be completed at a
later time if you become tired. Information about you will also be collected (such as your
age and gender).
This is an investigational study. About 167 patients will take part in this study. All will
be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
| Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
| Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |